Skip to main content

Research & Development

Pipeline

We are engaging in therapies for the treatment of acne, impetigo, psoriasis, rosacea and atopic dermatitis and various forms of warts caused by human papillomavirus (HPV) as well as a novel soft tissue implant in preclinical development. Upon receipt of FDA clearance, we intend to commercialize the programs through our self-directed sales team focusing on practices using dermatology products.

Cutanea Pipeline

Aktipak™
Xepi™
CLS008 - Psoriasis
CLS006 - Verruca Vulgaris
CLS001 - Rosacea
CLS001 - Acne
CLS001 - Atopic Dermatitis
CLS001 - VIN
CLS001 - Genital HPV
CLS003 - HPV/Verruca
CLS002 - Soft Tissue Augmentation
Key:
Preclinical
Phase 1
Phase 2
Phase 3
FDA Filing
Commercial

Clinical Trials

Cutanea Life Sciences is engaged in clinical research studies. Read about current research study openings.

SEARCH CLINICAL TRIALS

Cutanea Life Sciences, Inc.-sponsored clinical trials in patients are registered on ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

CLINICALTRIALS.GOV

About
What Makes Us Different